Experimental study of nano-hydroxyapatite/recombinant human bone morphogenetic protein-2 composite artificial bone.
OBJECTIVE
To investigate the repairing ability of nano-hydroxyapatite/recombinant human bone morphogenetic protein-2 (Nano-HA/rhBMP-2) composite artificial bone for bone defect and to provide evidence for its application in clinical repair of bone defect.


METHODS
The animal model of bone defect was made on unilateral radius of 90 New Zealand white rabbits, which were randomly divided into experimental group (group A, bone defect was repaired with Nano-HA/rhBMP-2 composite artificial bone), control group (group B, bone defect was repaired with Nano-HA artificial bone), and blank group (group C, bone defect was unrepaired). The repairing ability for bone defect was evaluated by gross observation, X-ray examination, scanning electron microscope, radionuclide bone imaging and biomechanical analysis at 4(th), 8(th), and 12th week postoperatively.


RESULTS
Both Nano-HA/rhBMP-2 composite artificial bone and Nano-HA artificial bone could stimulate new bone formation, but the former could stimulate more new bone formation and had better repairing ability for bone defect than that of the latter, with statistically significant difference (P <0.05).


CONCLUSIONS
Nano-HA/rhBMP-2 composite artificial bone has good repairing ability for bone defect and it is hopeful to become an ideal repairing material for bone defect.
Zhu
Weimin
W
Department of Sports Medicine, Shenzhen Second People's Hospital, Shenzhen, China.
Wang
Daping
D
Zhang
Xiaojun
X
Lu
Wei
W
Han
Yun
Y
Ou
Yangkan
Y
Zhou
Ke
K
Fen
Wenzhe
W
Liu
Jianquan
J
Peng
Liangquan
L
He
Chunlei
C
Zeng
Yanjun
Y
D000818:Animals; D001672:Biocompatible Materials / Q000008:administration & dosage / Q000627:therapeutic use; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000008:administration & dosage* / Q000627:therapeutic use*; D001861:Bone Regeneration / Q000187:drug effects* / Q000502:physiology; D018786:Bone Substitutes / Q000737:chemistry / Q000378:metabolism; D017886:Durapatite / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008297:Male; D053758:Nanoparticles; D011817:Rabbits; D011859:Radiography; D011877:Radionuclide Imaging; D011884:Radius / Q000000981:diagnostic imaging / Q000502:physiology / Q000601:surgery; D011994:Recombinant Proteins / Q000008:administration & dosage* / Q000627:therapeutic use*; D023822:Tissue Engineering / Q000379:methods*; D016212:Transforming Growth Factor beta / Q000008:administration & dosage* / Q000627:therapeutic use*; D014965:X-Rays
D001672:Biocompatible Materials; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D018786:Bone Substitutes; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2; D017886:Durapatite